Skip to content
10-K

Annual Report

Telomir Pharmaceuticals, Inc. TELO

0001493152-26-010625

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 12, 2026 34.38M sh
Shares Diluted FY 2025 · Dec 31, 2025 31.65M sh
Shares Diluted FY 2025 · Dec 31, 2024 29.54M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$3.69M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$5.07M
Stockholders Equity FY 2025 · Dec 31, 2025 $5.91M
Stockholders Equity FY 2025 · Dec 31, 2024 $643.04K
Stockholders Equity FY 2025 · Dec 31, 2023 $3.44M
Current Liabilities FY 2025 · Dec 31, 2025 $1.43M
Current Liabilities FY 2025 · Dec 31, 2024 $680.97K
Total Liabilities FY 2025 · Dec 31, 2025 $1.43M
Total Liabilities FY 2025 · Dec 31, 2024 $680.97K
Current Assets FY 2025 · Dec 31, 2025 $7.34M
Current Assets FY 2025 · Dec 31, 2024 $1.32M
Total Assets FY 2025 · Dec 31, 2025 $7.34M
Total Assets FY 2025 · Dec 31, 2024 $1.32M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.33
Eps Diluted restated FY 2025 · Dec 31, 2024 −$0.56
Eps Basic FY 2025 · Dec 31, 2025 −$0.33
Eps Basic restated FY 2025 · Dec 31, 2024 −$0.56
Sga Expense FY 2025 · Dec 31, 2025 $8.1M
Sga Expense FY 2025 · Dec 31, 2024 $9.64M
Rd Expense FY 2025 · Dec 31, 2025 $2.44M
Rd Expense FY 2025 · Dec 31, 2024 $2.24M
Net Income FY 2025 · Dec 31, 2025 −$10.41M
Net Income FY 2025 · Dec 31, 2024 −$16.53M